studies

breast cancer - HER2-positive, lapatinib vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsEGF104900, 2010 (REV) 1.35 [1.04; 1.75] TEACH (EGF105485), 2013 0.99 [0.74; 1.32] 1.16[0.86; 1.58]EGF104900, 2010 (REV), TEACH (EGF105485), 2013260%3,438moderatenot evaluable progression or deaths (PFS)detailed resultsEGF104900, 2010 (REV) 1.35 [1.07; 1.71] 1.35[1.07; 1.71]EGF104900, 2010 (REV)10%296NAnot evaluable RFS/DFSdetailed resultsTEACH (EGF105485), 2013 0.83 [0.69; 0.99] 0.83[0.69; 0.99]TEACH (EGF105485), 201310%3,147NAnot evaluable objective responses (ORR)detailed resultsEGF104900, 2010 (REV) 0.64 [0.28; 1.48] 0.64[0.28; 1.48]EGF104900, 2010 (REV)10%296NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-06-08 01:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 421

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons